Clinical Committee Co-Chairs
Dr. Fred Saad, MD FRCS, Professor and Chairman of Urology and Director of G-U Oncology at the University of Montreal Hospital Centers Canada
Fred Saad MD FRCS, is Professor and Chairman of Urology and Director of G-U Oncology at the University of Montreal Hospital Centers (CHUM). He holds the Raymond Garneau Chair in Prostate Cancer Research and is Director of clinical research and the molecular oncology research laboratory in Prostate Cancer. He is the past Chair of the National Cancer Institute of Canada G-U Group and the Canadian Urologic Oncology Group. He is presently the President of the Canadian Urologic Association. Dr Saad has played a leadership role in most of the practice changing clinical trials in advanced prostate cancer over the last 20 years and presently sits on 7 steering committees of ongoing international clinical trials. He serves on several international guidelines committees and sits on several editorial boards, including Lancet Oncology, JAMA Oncology, Nature Urology, Genitourinary Cancer and Urology. He has published over 400 peer-reviewed articles, over 2000 scientific abstracts 50 book chapters, and 8 books including ‘Understanding Prostate Cancer’ destined for patients that has sold over 200,000 copies to date. With a h-factor of 96 and over 41,000 citations he was listed as one of the world’s most cited scientists in 2017. Dr. Saad’s research interests include molecular prognostic markers, mechanisms of progression and new therapeutics in prostate cancer. He has over 40 clinical and basic research projects ongoing and has received over 30 million dollars in research grants. In 2014 he received the lifetime achievement award from the CHUM Research Center and in 2017 received the outstanding contribution award from The Prostate Cancer Canada Network. Given all his contributions to the field of prostate cancer he received the Order of Quebec in 2018.
Professor Wim Oyen, Professor of Nuclear Medicine and Molecular Imaging and Team Leader in Translational Molecular Imaging at The Institute of Cancer Research, England
Professor Wim Oyen is Professor of Nuclear Medicine and Molecular Imaging and Team Leader in Translational Molecular Imaging at The Institute of Cancer Research, and Consultant in Nuclear Medicine and Head of the Department of Nuclear Medicine at The Royal Marsden NHS Foundation Trust. He leads a programme to translate new radiopharmaceuticals developed at the ICR into clinical studies at The Royal Marsden and to introduce novel molecular imaging approaches for staging, treatment selection and monitoring of treatment response, as a means of optimising therapy for the individual cancer patient.
He is author on more than 600 articles in scientific journals, including Lancet Oncology, Nature Reviews Clinical Oncology and The Journal of Clinical Oncology, and more than 100 papers in The Journal of Nuclear Medicine. The scientific work of his group was awarded with The Marie Curie Award of the European Association of Nuclear Medicine in 1994 and in 2011. He was awarded with honorary membership of the European Society for Radiotherapy and Oncology in 2009.
Currently, he sits on the Board of the European Cancer Organisation (ECCO) and has served on the Board of the European Association of Nuclear Medicine (EANM) as the Congress Chair 2014-2016. As of January 2017, Professor Oyen is EANM President-elect and will start the two-year presidential term in 2019. He is actively involved in the European Organisation for Research and Treatment of Cancer (EORTC). He serves as Associate Editor of The Journal of Nuclear Medicine and is a member of the editorial board of the European Journal of Nuclear Medicine and Molecular Imaging and other international imaging journals.
Dr. Lionel S. Zuckier, MD, MBA, FRCPC, Professor and Medicine and Radiology, University of Ottawa and Director of Research, Division of Nuclear Medicine, The Ottawa Hospital, Ottawa Canada.
Lionel Zuckier MD, MBA, FRCPC, is Professor of Medicine and Radiology at University of Ottawa and Division Head Emeritus of the Division of Nuclear Medicine at the Ottawa Hospital. His current responsibilities include Director of Research in Nuclear Medicine and Chair of the Institutional Radiation Safety Committee. Dr. Zuckier trained in nuclear medicine and radiology at the Albert Einstein College of Medicine in New York where he also studied B-cell immunology and the targeting of tumours with radiolabeled immunologic moieties following receipt of a NIH Physician Scientist Training Award. He has published over 90 articles in research and review journals, authored multiple book chapters, and coedited several textbooks. Dr. Zuckier has participated in numerous imaging and therapeutic trials, including involvement in trials of Ra-223 for the treatment of boney metastases in prostate cancer, for which The Ottawa Hospital was an early research participant and clinical training site for other centres. Dr. Zuckier has organized symposia on radionuclide therapy of bone metastases and on the emergency response to radiation accidents. He has served as an examiner for the American Board of Radiology and the Royal College of Physicians and Surgeons of Canada, and currently is a member of Board of Directors of the Society of Nuclear Medicine and Molecular Imaging, General Clinical Nuclear Medicine Council.
Check back soon